webinar
August 17–21, 2025, Washington, DC, USA - Visit us at Booth 2230.
Read More
 Email:
 Phone:
Get A Quote

Cidofovir dihydrate

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Cidofovir dihydrate
Category Enzyme inhibitors
Catalog number BBF-03991
CAS 149394-66-1
Molecular Weight 315.22
Molecular Formula C8H18N3O8P
Purity >98%
Catalog Number Size Price Stock Quantity
BBF-03991 250 mg $298 In stock

Online Inquiry

Add to cart

Capabilities & Facilities

Fermentation Lab

4 R&D and scale-up labs

2 Preparative purification labs

Fermentation Plant

Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)

Product Description

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

  • Specification
  • Properties
  • Reference Reading
  • Price Product List
Related CAS 113852-37-2
Synonyms HPMPC dihydrate; Vistide dihydrate; (S)-HPMPC dihydrate
Storage Store at RT
IUPAC Name [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate
Canonical SMILES C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O
InChI InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0./s1
InChI Key FPKARFMSZDBYQF-ILKKLZGPSA-N
Appearance White Powder
Application Antiviral Agents
Antibiotic Activity Spectrum viruses
Boiling Point 609.5°C at 760 mmHg
Melting Point 260°C (dec)
Flash Point 322.4±34.3 °C
Density 1.76 g/cm3
Solubility Soluble in DMSO
1.Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.
Mendel DB1, Barkhimer DB, Chen MS. Antimicrob Agents Chemother. 1995 Sep;39(9):2120-2.
It has been observed that herpes simplex virus mutants with deficient or altered thymidine kinase activity are more susceptible to Cidofovir (CDV; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate) in tissue culture than are the parental strains. During infection of cells, the elevation of the dCTP pool by thymidine kinase mutant viruses is less than that induced by the wild-type virus. The competition between CDV diphosphate and dCTP at the viral polymerase is therefore changed in favor of CDV diphosphate, enhancing its activity.
2.Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
de Oliveira CB1, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD. Antiviral Res. 1996 Jul;31(3):165-72.
The antiviral inhibitory activity of Cidofovir [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate, HPMPC, GS-504] against adenovirus type 5 (Ad5) in the New Zealand rabbit ocular replication model was evaluated. The 50% inhibitory dose (ID50) of Cidofovir was determined to be 4.7-9.5 micrograms/ml against four adenoviruses (two Ad5, Ad8 and Ad14) by plaque reduction assay in A549 cells. Twenty-four New Zealand rabbits received intrastromal inoculation and topical application of 2 x 10(6) plaque-forming units (PFU) per eye of Ad5 McEwen, a clinical isolate. Cidofovir was administered topically at three different concentrations twice per day, beginning 16 h postinoculation and continuing for 20 consecutive days. The inhibitory effects were determined by measuring suppression of virus replication and by observation of the clinical effects. Compared to the placebo group, the 1% and 0.5% Cidofovir-treated groups showed significantly reduced Ad5 ocular titers, fewer days of viral shedding and less severe subepithelial opacities (P = 0.
3.Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.
Davis JL1, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Arch Ophthalmol. 1997 Jun;115(6):733-7.
OBJECTIVE: To describe intraocular inflammation due to treatment with intravenous cidofovir dihydrate for cytomegalovirus retinitis.
4.Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.
Banker AS1, Arevalo JF, Munguia D, Rahhal FM, Ishimoto B, Berry C, De Clercq E, Ochabski R, Taskintuna I, Freeman WR. Am J Ophthalmol. 1997 Aug;124(2):168-80.
PURPOSE: To evaluate the decrease in intraocular pressure associated with cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate; HPMPC) intravitreal injections.

Bio Calculators

  • Solution Dilution Calculator
  • Molecular Weight Calculator
  • Molarity Calculator
Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

Calculate
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
g/mol
g

Recently viewed products

Ergocristine | Cidofovir dihydrate

Online Inquiry

Copyright © 2025 BOC Sciences. All rights reserved.

USA

  • International : 
    US & Canada (Toll free):
  • Fax:
  • Email:

UK

  • Tel:
  • Email:
cartIcon
Inquiry Basket
Loading ......
Delete selected Go to checkout